RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Clinical trials for RELAPSED/REFRACTORY B-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers that have not responded to standard therapy or have returned. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to see if it is safe and helps patien…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 17, 2026 05:20 UTC
-
New dual-target CAR-T therapy enters human testing for hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new type of cell therapy that uses a virus to deliver two cancer-fighting targets (CD19 and CD20) directly into the body. It is for adults with B-cell blood cancers that have relapsed or not responded to standard treatments. The main goals are to ch…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New injection shows promise for tough blood cancers in early trial
Disease control Recruiting nowThis study is testing a new treatment called IASO208 for people with certain blood cancers (like lymphoma) that have returned or stopped responding to standard therapy. The goal is to see if it is safe and to get an early look at how well it works. About 12 adults aged 18 to 75 w…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for tough blood cancers? early trial launches for ZZSW-01
Disease control Recruiting nowThis early-phase study tests a new drug called ZZSW-01 in 6 adults with certain blood cancers (B-cell malignancies) that have returned or not responded to prior treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants w…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug trial aims to tame tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called UBX-303061 in people with certain blood cancers (B-cell malignancies) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. About 94 adults will take pa…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Ubix Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for hard-to-treat blood cancers? AC676 enters human testing.
Disease control Recruiting nowThis early-stage study tests a new drug called AC676 in about 60 adults with B-cell blood cancers (like certain leukemias and lymphomas) that have returned or not improved after at least two prior treatments. The main goals are to find a safe dose and check for side effects. Rese…
Matched conditions: RELAPSED/REFRACTORY B-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated May 06, 2026 16:13 UTC